1. Milnacipran hydrochloride, Dalcipran registered trade mark, Toledomin registered trade mark. Drugs Future. 21(1): 88–89.
2. Solles A, Serre C, Sutet P, Briley M. (1991). Milnacipran a potent antidepressant with combined NA and 5-HT mechanism of action. In: Ansseau M, Von Frenkell R, Franck G (eds) Biological Markers of Depression: state of the art. Excerpta Medica, Ams terdam, 197–202.
3. Puozzo C, Rostin M, Montastruc JL, Houin G. (1987) Absolute bioavailability study of midalcipran (F2207) in volunteers. In: Aiache, JM, Hirtz J (eds) Proc-Eur Congr Biopharm Pharmacokinet, 3rd; Impr Univ Clermont-Ferrand, Clermont-Ferrand, FR: 59–68, AVAIL: 59–68.
4. Puozzo C, Filaquier C, Briley M. (1985). Plasma levels of F2207, a novel antidepressant after single oral adminsitration in volunteers. Br J Clin Pharm, 20: 291.
5. Puozzo C, Duchene P, Bromet M, Filaquier C, Zorza G. (1996): Determination of milnacipran (F2207) and its glucuroconjugate in plasma, blood and urine by high performance liquid chromatography with fluorescence detection. J Chromatogr. To be published.